Absci Corporation (ABSI) Earnings Call Transcripts
Absci Corporation's Latest Earnings Call - June 9, 2026
In the second quarter of fiscal year 2026, Absci Corporation reported significant advancements in its clinical pipeline, particularly with ABS-201 targeting androgenetic alopecia (AGA) and endometriosis. The company is on track to deliver two Phase II clinical readouts within the next 24 months, which could be pivotal for its stock performance. Management highlighted that the cost to bring drugs to the clinic has been reduced to $10-$15 million, a substantial decrease from the traditional $50 million, signaling operational efficiency and potential for higher margins going forward.
Reported metrics
| Metric | Value |
|---|---|
| Phase II Readouts | 2 (positive) |
| Development Cost | $10-$15 million (positive) |
| AGA Market Opportunity | $25 billion (positive) |
| Endometriosis Market Opportunity | $4.5 billion (positive) |
| Interim Readout Timeline | 13 weeks (positive) |
Guidance from management
Management is optimistic about the upcoming clinical data releases and has maintained a focus on advancing ABS-201 through its pipeline, with no changes to previous guidance indicated during the call.
What analysts pressed on
Analysts expressed concerns about the competitive landscape in the hair regrowth market and the efficacy of ABS-201 compared to existing treatments. There were inquiries regarding the timeline for data releases and potential delays that could impact investor sentiment.
Main topics on the call
- Clinical Pipeline Progress — Absci is set to have two Phase II clinical readouts for ABS-201 targeting AGA and endometriosis within the next 24 months. CEO Sean McClain stated, "we're actually starting to see the drugs that we've designed with our A...
- Cost Efficiency in Drug Development — Management emphasized a significant reduction in drug development costs, stating, "we've been able to get drugs into the clinic for roughly $10 million to $15 million of investment when traditionally that takes $50-plus ...
- Market Opportunity for ABS-201 — The market opportunity for ABS-201 in AGA is estimated at $25 billion in the U.S. and $40 billion globally. McClain noted, "we see this playing really nicely into this total vitality market that we're seeing evolve."
- Endometriosis Potential — Management highlighted the significant unmet need in endometriosis treatment, with a market opportunity of over $4.5 billion. The CEO stated, "the need for therapy here is extremely high," indicating strong growth potent...
Read the full Absci Corporation transcript (June 9, 2026) → Summary generated from the call transcript; every figure above is stated by management on the record.
About Absci Corporation
Absci Corporation (ABSI) is a publicly listed company in the Biotechnology industry, within the Health Care sector. It trades on NasdaqGS and is based in US. EarningsCalls.dev maintains a free, full-text archive of its earnings call transcripts — 30 calls on record spanning November 10, 2022 to June 9, 2026. Every transcript is split into speaker-by-speaker segments with headline metrics, free to read or available through our REST API.
Earnings Call History
EarningsCalls.dev has 30 Absci Corporation earnings call transcripts on record, spanning November 10, 2022 to June 9, 2026. Based on this history, Absci Corporation reports quarterly. The most recent call on file is dated June 9, 2026. The full list is below — each row opens the complete, free-to-read transcript.
- Ticker
- ABSI
- Exchange
- NasdaqGS
- Country
- US
- Sector
- Health Care
- Industry
- Biotechnology
- Calls on record
- 30
- First call
- November 10, 2022
- Most recent
- June 9, 2026
- Reporting cadence
- quarterly